Lupus Nephritis Clinical Trial
Official title:
A Phase 1/2, Open-Label, Multicenter Study of KYV-101, an Autologous Fully-Human Anti-CD19 Chimeric Antigen Receptor T-Cell (CD19 CAR T) Therapy, in Subjects With Refractory Lupus Nephritis (KYSA-3)
A Study of Anti-CD19 Chimeric Antigen Receptor T Cell Therapy for Subjects With Refractory Lupus Nephritis
Systemic lupus erythematosus (SLE) is a chronic autoimmune disease characterized by a wide spectrum of organ involvement and disease severity. Renal involvement (categorized as lupus nephritis [LN]) may occur in approximately 50% of SLE patients and is marked by proteinuria, microscopic hematuria, and varying degrees of renal insufficiency. B cells play a central role in the pathogenesis of SLE and LN, with autoantibodies developing as an early finding, and local, tissue resident B cells producing pathogenic autoantibodies and driving inflammation and tissue damage over time. CD19-targeted chimeric antigen receptor (CAR) T cells harness the ability of cytotoxic T cells to directly and specifically lyse target cells to effectively deplete B cells in the circulation and in lymphoid and potentially non-lymphoid tissues. KYV-101, a fully human anti-CD19 CAR T-cell therapy, will be investigated in adult subjects with refractory lupus nephritis. ;
| Status | Clinical Trial | Phase | |
|---|---|---|---|
| Recruiting |
NCT02936375 -
The Iguratimod Effect on Lupus Nephritis (IGeLU)
|
Phase 2 | |
| Completed |
NCT03597464 -
Aurinia Renal Assessments 2: Aurinia Renal Response in Lupus With Voclosporin
|
Phase 3 | |
| Recruiting |
NCT01226147 -
Efficacy and Safety of Tamibarotene(AM80) for Lupus Nephritis
|
Phase 2 | |
| Completed |
NCT01206569 -
Long-Acting Tacrolimus for the Treatment of Resistant Lupus Nephritis
|
Phase 4 | |
| Active, not recruiting |
NCT00569101 -
A Pilot Study for the Efficacy and Safety of Tacrolimus in the Treatment of Refractory Lupus Nephritis
|
Phase 2 | |
| Terminated |
NCT00368264 -
TNF Blockade With Remicade in Active Lupus Nephritis WHO Class V (TRIAL )
|
Phase 2/Phase 3 | |
| Completed |
NCT00371319 -
Comparing the Efficacy of Tacrolimus and Mycophenolate Mofetil for the Initial Therapy of Active Lupus Nephritis
|
Phase 4 | |
| Completed |
NCT00298506 -
Study to Assess the Efficacy and Safety of FK506 Combined With Mycophenolate Mofetil (MMF) in Lupus Nephritis (III/IV/V)
|
N/A | |
| Completed |
NCT00094380 -
Treating Systemic Lupus Erythematosus (SLE) Patients With CTLA4-IgG4m (RG2077)
|
Phase 1/Phase 2 | |
| Terminated |
NCT04376827 -
A Study of Guselkumab in Participants With Active Lupus Nephritis
|
Phase 2 | |
| Completed |
NCT03610516 -
Safety, Pharmacokinetics and Preliminary Efficacy Study of CFZ533 in Patients With Lupus Nephritis.
|
Phase 2 | |
| Recruiting |
NCT03526042 -
Angiotensin-II Receptor Antibodies Blockade With Losartan in Patients With Lupus Nephritis
|
N/A | |
| Withdrawn |
NCT03859570 -
Pentoxifylline in Lupus Nephritis
|
Phase 4 | |
| Completed |
NCT03664908 -
Detection of Anti-glomerular Basement Membrane Antibodies (Anti-GBM): a Promising Biomarker for Lupus Nephritis (LN)?
|
N/A | |
| Completed |
NCT01085097 -
A Study of Laquinimod in Participants With Systemic Lupus Erythematosus (SLE) Active Lupus Nephritis
|
Phase 2 | |
| Active, not recruiting |
NCT05704088 -
SGLT2 Inhibitors Between Reno Protective Effects and Impact on Bone and Mineral Disease Among Lupus Nephritis Patients
|
Phase 4 | |
| Not yet recruiting |
NCT06429800 -
A Study to Evaluate the Safety and Preliminary Efficacy of ATA3219 in Participants With Lupus Nephritis
|
Phase 1 | |
| Recruiting |
NCT02226341 -
ACTHar in the Treatment of Lupus Nephritis
|
Phase 4 | |
| Recruiting |
NCT02453997 -
Mycophenolic Acid Pharmacokinetics and Pharmacogenomics in Lupus Nephritis
|
N/A | |
| Completed |
NCT01470183 -
Lupus Nephritis Biomarker Study: Baseline Characteristics of Patients
|
N/A |